Cargando…
A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer.
Sixty patients with advanced breast cancer unresponsive to tamoxifen have been randomised to receive four course of mitozantrone, 14 mg m-2 (n = 30) intravenously every 3 weeks (9 weeks total) or megesterol acetate, 160 mg bd (n = 30). One in three patients (11 from each group) had substantial disea...
| Autores principales: | , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
1992
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977824/ https://www.ncbi.nlm.nih.gov/pubmed/1503915 |